{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:07:26Z","timestamp":1791209246881,"version":"4.1.0"},"reference-count":20,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"myDNA Life Australia"},{"name":"UKRI Living Laboratory for Precision Medicine"},{"name":"Agena BioScience"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,16]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pharmacogenomic (PGx) panel testing may reduce adverse drug reactions (ADRs), treatment failures and downstream healthcare use by aligning prescribing with germline genetic variation. The PREPARE trial reported an approximately 30% reduction in clinically relevant ADRs using a pre-emptive multigene panel, but its open-label design, patient-reported endpoint and subsequent methodological critiques limit its use for National Health Service (NHS) decision-making. Whether panel-based PGx delivers benefit in acute NHS secondary care, where prescribing is time-critical, patients are older and multimorbid and outcomes can be linkage-adjudicated, remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>PHOENIX is a pragmatic, pilot, parallel-group, individually randomised controlled trial with blinded outcome adjudication, in NHS Greater Glasgow and Clyde (NHSGGC) hospitals and NHS Golden Jubilee National Hospital. Adults newly prescribed an eligible PGx-relevant index drug are identified through a data-driven screening system integrating electronic prescribing, community prescribing linkage and record review and randomised 1:1 to PGx-guided care or standard care with delayed PGx testing. In the intervention arm, buccal-swab DNA is genotyped (Clinical Laboratory Improvement Amendments\/College of American Pathologist (CLIA\/CAP)-accredited laboratory) and a Clinical Pharmacogenetics Implementation Consortium (CPIC)\/Dutch Pharmacogenetics Working Group (DPWG)-based report returned within approximately 10 days; results are research-use-only. The trial aims to recruit 2000\u20134000\u2009participants constrained by a fixed operational end-date (30 September 2026). The primary outcome is index-drug-related ADR or treatment failure within 3\u2009months, adjudicated using Common Terminology Criteria for Adverse Events (CTCAE) V.6 and validated causality tools, with deterministic linkage via the West of Scotland Safe Haven. Secondary outcomes include ADR severity, hospitalisations, mortality, actionable prescribing uptake, biomarker levels, EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) and healthcare utilisation. The primary analysis is intention-to-treat logistic regression adjusted for stratification factors; a within-trial cost-utility analysis estimates cost per quality-adjusted life year (QALY).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Approved by Scotland A Research Ethics Committee (24\/SS\/0064; IRAS 344412; NHS R&amp;I INGN24MG113). Co-sponsors are NHSGGC and the University of Glasgow. Findings will be disseminated via peer-reviewed publication, conferences, patient and public involvement and engagement-co-produced lay summaries and the trial website.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT06907784\">NCT06907784<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-121606","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:31Z","timestamp":1791207331000},"page":"e121606","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["PHOENIX: a study protocol for a pilot randomised controlled trial of pre-emptive pharmacogenomic panel testing in acute care settings with health economic evaluations"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06907784","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct06907784","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stefanie","family":"Lip","sequence":"first","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-6573","authenticated-orcid":false,"given":"Pieter Theo","family":"Pepler","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7262-7000","authenticated-orcid":false,"given":"Alex","family":"McConnachie","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J","family":"Sheffield","sequence":"additional","affiliation":[{"name":"MyDNA, GenebyGene, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Mostafa","sequence":"additional","affiliation":[{"name":"MyDNA, GenebyGene, Melbourne, Victoria, Australia"},{"name":"Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-647X","authenticated-orcid":false,"given":"Linsay","family":"McCallum","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bennett","sequence":"additional","affiliation":[{"name":"MVLS Innovation Engagement and Enterprise, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Frater","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriona","family":"Brooksbank","sequence":"additional","affiliation":[{"name":"West of Scotland Innovation Hub, NHSGGC, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Macbride-Stewart","sequence":"additional","affiliation":[{"name":"Pharmacy Services, NHSGGC, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M","family":"Pratt","sequence":"additional","affiliation":[{"name":"Agena Bioscience Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-9314","authenticated-orcid":false,"given":"Brandon","family":"Franklin","sequence":"additional","affiliation":[{"name":"Agena Bioscience Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Sheffield","sequence":"additional","affiliation":[{"name":"MyDNA, GenebyGene, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-5808","authenticated-orcid":false,"given":"Sandosh","family":"Padmanabhan","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100506352359000_16.10.e121606.1","unstructured":"NHS England . Accelerating genomic medicine in the NHS. London, 2022."},{"key":"2026100506352359000_16.10.e121606.2","unstructured":"Royal College of Physicians BPS . Personalised prescribing: using pharmacogenomics to improve patient outcomes. London Royal College of Physicians and British Pharmacological Society; 2022."},{"key":"2026100506352359000_16.10.e121606.3","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/bcp.70109","article-title":"Pharmacogenomics in the UK National Health Service: Progress towards implementation","volume":"91","author":"McDermott","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"2026100506352359000_16.10.e121606.4","doi-asserted-by":"crossref","first-page":"e195345","DOI":"10.1001\/jamanetworkopen.2019.5345","article-title":"Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users","volume":"2","author":"Chanfreau-Coffinier","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026100506352359000_16.10.e121606.5","unstructured":"National Institute for Health and Care Excellence . CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. 2024."},{"key":"2026100506352359000_16.10.e121606.6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14704"},{"key":"2026100506352359000_16.10.e121606.7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"2026100506352359000_16.10.e121606.8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cpt.3749","article-title":"Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study","volume":"118","author":"Guchelaar","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026100506352359000_16.10.e121606.9","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0140-6736(23)00854-1","article-title":"The PREPARE study: benefits of pharmacogenetic testing are unclear","volume":"401","author":"Curtis","year":"2023","journal-title":"Lancet"},{"key":"2026100506352359000_16.10.e121606.10","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0140-6736(23)00853-X","article-title":"The PREPARE study: benefits of pharmacogenetic testing are unclear","volume":"401","author":"Rogers","year":"2023","journal-title":"Lancet"},{"key":"2026100506352359000_16.10.e121606.11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(23)00852-8","article-title":"The PREPARE study: benefits of pharmacogenetic testing are unclear - Authors\u2019 reply","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"2026100506352359000_16.10.e121606.12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(23)00855-3","article-title":"The PREPARE study: benefits of pharmacogenetic testing are unclear","volume":"401","author":"Van der Linden","year":"2023","journal-title":"Lancet"},{"key":"2026100506352359000_16.10.e121606.13","doi-asserted-by":"crossref","unstructured":"Sharma V , McDermott J , Keen J , et al . Designing an interoperable solution to support pharmacogenomic-guided prescribing in primary care: an implementer report. BMJ Health Care Inform 2025;32. doi:10.1136\/bmjhci-2024-101163","DOI":"10.1136\/bmjhci-2024-101163"},{"key":"2026100506352359000_16.10.e121606.14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cpt.1030","article-title":"Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?","volume":"103","author":"Hughes","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2026100506352359000_16.10.e121606.15","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0397-9"},{"key":"2026100506352359000_16.10.e121606.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-022-01259-8"},{"key":"2026100506352359000_16.10.e121606.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-022-00572-8"},{"key":"2026100506352359000_16.10.e121606.18","doi-asserted-by":"crossref","first-page":"111792","DOI":"10.1016\/j.jclinepi.2025.111792","article-title":"Improving the completeness and transparency of protocols and reports of randomized trials: SPIRIT 2025 and CONSORT 2025","volume":"182","author":"Moher","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"2026100506352359000_16.10.e121606.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-010-0319-7"},{"key":"2026100506352359000_16.10.e121606.20","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.89.9.1322"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-121606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:34Z","timestamp":1791207334000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-121606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjopen-2026-121606"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-121606","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}